secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2026-02-27T23:59:59+00:00
Accession:  0001193125-26-079342
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Q4 GAAP net loss $22.8M ($0.42/sh), completes $150M offering, cash runway to 1H 2028
--------------------------------------------------------------------------------

- Cash $48.3M at Dec 31, 2025; after Feb 2026 $150M offering net $140.4M, runway through 1H 2028.
- GAAP net loss Q4 2025 ($22.8M)/($0.42) vs ($29.2M)/($0.55) in Q4 2024; full year ($101.7M)/($1.90) vs ($134.9M)/($2.58).
- R&D expenses Q4 2025 $17.6M vs $23.5M in Q4 2024; full year $77.0M vs $116.4M.
- Barbara Klencke appointed permanent CMO; completed $150M registered equity offering in Feb 2026.
- Clinical milestones: evorpacept biomarker data; ASPEN-09 enrollment expanded to 120 pts, topline mid-2027; ALX2004 safety data 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000119312526079342/0001193125-26-079342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000119312526079342/alxo-20260227.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-079342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer